Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Gefitinib-induced paronychia: response to autologous platelet-rich plasma.

Kwon SH, Choi JW, Hong JS, Byun SY, Park KC, Youn SW, Huh CH, Na JI.

Arch Dermatol. 2012 Dec;148(12):1399-402.

PMID:
22986691
2.

Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor.

Dainichi T, Tanaka M, Tsuruta N, Furue M, Noda K.

Dermatology. 2003;207(3):324-5. No abstract available.

PMID:
14571080
3.

Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer.

Chang GC, Yang TY, Chen KC, Yin MC, Wang RC, Lin YC.

J Clin Oncol. 2004 Nov 15;22(22):4646-8. No abstract available.

PMID:
15542815
4.

Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor.

Nakano J, Nakamura M.

J Dermatol. 2003 Mar;30(3):261-2. No abstract available.

PMID:
12692371
5.

[A case of lung adenocarcinoma successfully treated with dose-reescalated gefitinib after resistance was acquired].

Hirano S, Sano K, Morii S, Morita A, Takeda Y, Uruga K, Sugiyama H, Kobayashi N, Kudo K.

Gan To Kagaku Ryoho. 2009 Aug;36(8):1333-6. Japanese.

PMID:
19692773
6.

[Case of bilateral pneumothorax observed during the administration of gefitinib for lung adenocarcinoma with multiple pulmonary metastases].

Fukai M, Mori M, Namba Y, Fushitani K, Nakazawa Y, Yano Y, Niinaka M, Kimura H, Naka N, Okada T, Nakagawa M, Yokota S.

Nihon Kokyuki Gakkai Zasshi. 2008 Jun;46(6):483-7. Review. Japanese.

PMID:
18592995
8.

Acute gefitinib-induced pneumonitis.

Ohyanagi F, Ando Y, Nagashima F, Narabayashi M, Sasaki Y.

Int J Clin Oncol. 2004 Oct;9(5):406-9.

PMID:
15549594
9.

Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib.

Maruyama K, Chinda J, Kuroshima T, Kabara M, Nakagawa N, Fujino T, Yamamoto Y, Ohsaki Y, Ogawa Y, Hasebe N.

Intern Med. 2015;54(7):823-6. doi: 10.2169/internalmedicine.54.3661. Epub 2015 Apr 1.

10.

Acute paronychia caused by lapatinib therapy.

Rigopoulos D, Gregoriou S, Belyayeva Y, Larios G, Gkouvi A, Katsambas A.

Clin Exp Dermatol. 2009 Jan;34(1):94-5. doi: 10.1111/j.1365-2230.2008.02928.x. Review. No abstract available.

PMID:
19076807
11.

Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker.

Binder D, Buckendahl AC, Hübner RH, Schlattmann P, Temmesfeld-Wollbrück B, Beinert T, Suttorp N.

Med Oncol. 2012 Mar;29(1):193-8. doi: 10.1007/s12032-010-9767-x. Epub 2010 Dec 14.

PMID:
21327738
12.

Progressive multiple cystic changes in both lungs in a patient treated with gefitinib for lung adenocarcinoma with multiple lung metastases.

Ryu YJ, Chun EM, Lee SN, Shim SS.

Korean J Radiol. 2014 Mar-Apr;15(2):300-4. doi: 10.3348/kjr.2014.15.2.300. Epub 2014 Mar 7.

13.

Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy.

Aoe K, Hiraki A, Murakami T, Maeda T, Umemori Y, Katayama H, Eda R, Takeyama H.

Anticancer Res. 2005 Jan-Feb;25(1B):415-8.

14.

Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.

Nakamichi S, Kubota K, Horinouchi H, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Tamura T.

Jpn J Clin Oncol. 2013 Apr;43(4):422-5. doi: 10.1093/jjco/hyt012. Epub 2013 Feb 13.

PMID:
23410901
15.

[Two lung adenocarcinoma patients with multiple brain metastasis treated with Gefitinib and surviving more than 2 years].

Matsuyama W, Yamamoto M, Machida K, Mitsuyama H, Watanabe M, Higashimoto I, Osame M, Arimura K.

Nihon Kokyuki Gakkai Zasshi. 2006 Sep;44(9):653-8. Japanese.

PMID:
17037411
16.

Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.

Graves JE, Jones BF, Lind AC, Heffernan MP.

J Am Acad Dermatol. 2006 Aug;55(2):349-53.

PMID:
16844529
17.

Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib.

Masutani K, Fujisaki K, Maeda H, Toyonaga J, Inoshima I, Takayama K, Katafuchi R, Hirakata H, Tsuruya K, Iida M.

Clin Exp Nephrol. 2008 Oct;12(5):398-402. doi: 10.1007/s10157-008-0066-1. Epub 2008 Jun 25.

PMID:
18575950
18.

[A case of lung adenocarcinoma effectively treated with sivelestat and corcicosteroid for drug-induced lung disease due to gefitinib].

Mori M, Iwasaki T, Nakazawa Y, Namba Y, Niinaka M, Yano Y, Kitada S, Kimura H, Naka N, Okada T, Nakagawa M, Maekura R, Yokota S.

Nihon Kokyuki Gakkai Zasshi. 2008 Mar;46(3):232-6. Japanese.

PMID:
18409572
19.

Gefitinib-induced interstitial lung disease-addition of intravenous cyclophosphamide to corticosteroids is a valuable treatment option: A case report.

Goto Y, Hojo M, Takeda Y, Kobayashi N, Kudo K.

Med Oncol. 2010 Sep;27(3):753-5. doi: 10.1007/s12032-009-9280-2. Epub 2009 Aug 4.

PMID:
19653137
20.

Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.

Wang KF, Chang CY, Chang SC, Liu YC, Yuan MK, Yang YH.

J Chin Med Assoc. 2013 Mar;76(3):173-5. doi: 10.1016/j.jcma.2013.01.012. Epub 2013 Feb 27.

Supplemental Content

Support Center